

FOR IMMEDIATE RELEASE

Media Contact: Robin Embry
Lovell Communications
robin@lovell.com
615.297.7766

Diatherix Laboratories Debuts ABRx™ Antibiotic Resistance Panel

Novel test detects 17 multidrug resistance genes to help combat antibiotic resistant bacteria

Nashville, TN (October 4, 2016) – [Diatherix Laboratories, LLC](#), a leading provider of multiplex diagnostic solutions, has launched the ABRx™ Antibiotic Resistance Panel, a diagnostic test for detection of 17 antibiotic resistance genes. Used on properly collected specimens taken directly from the infectious process, the ABRx™ Panel can enhance result times and diagnostic accuracy, providing physicians and pharmacists with clinically important information to benefit both patient outcomes and hospital quality measures.

The ABRx™ Panel detects clinically problematic and prevalent antibiotic resistance genes that lead to resistance to some of the most commonly prescribed antibiotics: penicillins, cephalosporins, monobactams, carbapenems, macrolides and fluoroquinolones. The molecular identification of antibiotic resistance is an innovative approach in clinical diagnostics when compared to antibiotic susceptibility testing performed in routine laboratories.

“Failure to properly identify bacteria’s underlying gene resistance mechanisms can result in treatment failure and a cascading series of negative outcomes for patients, healthcare providers, payors and the general population,” said Diatherix Laboratories’ Chief Executive Officer Dennis Grimaud. “With utilization of the ABRx™ Panel, clinicians can make better informed treatment decisions that can lead to improved patient health, reduced hospital stays, decreased readmissions and overall costs. Most importantly, it can help assist in slowing the frightening pace of antibiotic resistance.”

Strategies to reduce antibiotic resistance have received an unprecedented amount of attention in recent years with calls to action from the White House, the Centers for Disease Control and Prevention and numerous professional medical associations. An increasing number of public health leaders around the globe, including leaders from the World Health Organization, have sounded the alarm that the world may be entering a “post-antibiotic era” in which some of the most dependable medicines are rendered useless, and common infections can once again kill.

More information about the ABRx™ Panel can be found in this [technical bulletin](#).

ABOUT DIATHERIX

Diatherix Laboratories, LLC, a subsidiary of Eurofins Scientific, a global leader in food, environmental and pharmaceutical testing, is located in the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. Diatherix operates as an independent, high complexity, CAP-accredited clinical laboratory providing advanced multiplex molecular diagnostic services to assist healthcare providers in the simultaneous detection of bacteria, viruses, parasites, *Candida* and antibiotic resistance related to infectious diseases – providing one-day results and single-sample collection. For more information, please visit the company's website at www.diatherix.com.